EBRD fully exits Ibnsina Pharma
Updated 2/5/2025 9:40:00 AM
Arab Finance: The European Bank for Reconstruction and Development (EBRD) has fully exited its remaining 8.8% equity in Ibnsina Pharma via the Egyptian Exchange (EGX), according to a press release.
The lender acquired a 20% stake in Ibnsina Pharma in 2015 through a combination of primary and secondary transactions to finance the development of its warehouses, distribution centers, and overall supply chain.
Omar Abdel Gawad, the CEO of Ibnsina Pharma, commented: “Our partnership with the EBRD has been invaluable to our growth story and expansion – a key part of our journey to becoming the number one player in the Egyptian market.”
Hassan Massoud, who oversees the EBRD’s private equity business in the southern Mediterranean, said: “The scale and timing of this transaction is a testament to the depth of the Egyptian Exchange (EGX) as a credible exit venue for successful private equity investments.”
Established in 2000, Ibnsina Pharma is an Egyptian joint stock firm that specializes in the distribution of pharmaceutical products.
The Cairo-based company ranked first among pharmaceutical distribution firms in Egypt for the second consecutive year.
Related News
